Nissay Asset Management Corp Japan ADV Boosts Position in Gilead Sciences, Inc. $GILD

Key Points

• Nissay Asset Management Corp Japan ADV increased its stake in Gilead Sciences, Inc. by 9.6% during the 1st quarter, now holding 311,521 shares valued at approximately $34.9 million.
• Insider transactions revealed that Johanna Mercier sold 28,000 shares, decreasing her position by 19.7%, while CFO Andrew D. Dickinson also sold shares, reflecting notable insider activity in recent months.
• Gilead Sciences reported a Q2 EPS of $2.01, beating estimates, with revenue reaching $7.08 billion, and provided guidance for FY 2025 EPS between 7.95-8.25.

Nissay Asset Management Corp Japan ADV increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 9.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 311,521 shares of the biopharmaceutical company's stock after buying an additional 27,278 shares during the period. Nissay Asset Management Corp Japan ADV's holdings in Gilead Sciences were worth $34,906,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of GILD. Brighton Jones LLC raised its holdings in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Bison Wealth LLC purchased a new position in shares of Gilead Sciences in the 4th quarter worth approximately $215,000. Algert Global LLC bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $3,214,000. Cary Street Partners Financial LLC purchased a new stake in Gilead Sciences during the fourth quarter valued at approximately $586,000. Finally, CoreCap Advisors LLC boosted its stake in Gilead Sciences by 2,295.0% in the fourth quarter. CoreCap Advisors LLC now owns 24,668 shares of the biopharmaceutical company's stock valued at $2,279,000 after acquiring an additional 23,638 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded down $0.98 during trading on Wednesday, reaching $114.78. 1,922,813 shares of the company traded hands, compared to its average volume of 8,100,031. The stock has a market cap of $142.42 billion, a P/E ratio of 22.86, a PEG ratio of 0.79 and a beta of 0.36. The firm's fifty day simple moving average is $113.77 and its 200 day simple moving average is $109.99. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 12-month low of $79.64 and a 12-month high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter last year, the business earned $2.01 earnings per share. The firm's revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. Gilead Sciences's dividend payout ratio (DPR) is currently 62.95%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $296,325.00. Following the sale, the chief financial officer owned 160,110 shares of the company's stock, valued at $18,977,838.30. The trade was a 1.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the sale, the director owned 8,920 shares of the company's stock, valued at $978,880.80. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 82,000 shares of company stock worth $9,371,330. Company insiders own 0.27% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on GILD. Royal Bank Of Canada upped their price target on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. UBS Group raised their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Dbs Bank upgraded Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Finally, Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a research report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and an average price target of $115.39.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.